Hendrik-Tobias Arkenau, founding Medical Director of the Sarah Cannon Research Institute UK (SCRI UK), provides his expert insight into the key data for solid tumours and what he expects at the 2019 ESMO Congress. He discusses the importance of understanding tumour biology in directing therapeutic advances and the clinical management of patients with solid tumours.1/3 Next Interview
Dirk Jäger, Director of the National Centre for Tumour Diseases in Heidelberg, Germany, provides his expert insight into the latest data relating to the management of solid tumours, including the different immunotherapy approaches, how these could guide future approaches in clinical practice and what he expects from the 2019 ESMO Congress.2/3 Next Interview
Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven and University Hospitals Gasthuisberg, Belgium, provides his expert insight into the challenges in treating solid tumours and how there has been a shift towards immunotherapy, including combination and sequential therapy approaches, as well as the use of biomarkers. He discusses these approaches to managing solid tumours, including gastrointestinal (GI) tumours, and what he thinks will be the focus at the 2019 ESMO Congress.3/3 Leave Feedback
Learning Objectives & Overview
Stay up to date with the latest developments in the treatment of solid tumours with our expert summary of what is expected at the ESMO Congress in Barcelona, Spain, 27 September–1 October 2019.
Dr Hendrik-Tobias Arkenau (Executive Medical Director of the Sarah Cannon Research Institute, London, UK), Prof. Dirk Jäger (Head of the Medical Oncology Department, University Hospital Heidelberg, Germany) and Prof. Eric Van Cutsem (Head of Clinical Digestive Oncology, KU Leuven, Belgium) review the most important challenges in treating solid tumours and how emerging data expected at the ESMO Congress 2019 could influence the future clinical management of solid tumours.
After watching this touchEXPERT OPINIONS, you should be able to:
- Identify solid tumour types with the greatest unmet clinical need in terms of effective new therapy approaches
- Discuss emerging data for new immunotherapies and targeted therapies in solid tumours and know how to identify patients that may benefit from these new treatments
- Evaluate the rationales for different combination and sequential therapy approaches with new agents in solid tumours